| Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil. | |
| | |
MedLine Citation:
|
PMID: 19196368 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Development of antineutrophil cytoplasmic antibody (ANCA) during therapy with propylthiouracil (PTU) is not uncommon and PTU-induced ANCA-positive vasculitis is also reported. The aim of this study was to assess the presence and clinical significance of ANCA positivity in Graves' patients treated with PTU. Newly diagnosed Graves' disease patients (prospective group, n = 58) were evaluated before and during therapy with PTU to investigate the development of ANCA positivity. ANCA positivity is also investigated in previously diagnosed Graves' patients who had already been receiving PTU treatment (cross-sectional group, n = 51). Comparisons with Hashimoto thyroiditis (n = 55) and toxic nodular goitre (n = 20) patients, and healthy control subjects (n = 20) were carried out to define the possible influence of hyperthyroidism and/or thyroid autoimmunity on ANCA positivity. At baseline evaluation, ANCA was negative in all newly diagnosed Graves' patients. Only 28 of the 58 patients in prospective group completed 2 years of follow-up which occurred at 3-month intervals. ANCA positivity was detected 32.1% (n = 9) in a mean period of 11.7 +/- 6.1 months in prospective group. Only two (3.9%) patients in a cross-sectional group had ANCA positivity in a mean treatment period of 7.6 +/- 4.6 months. None of the patients with ANCA positivity developed symptoms and signs related to vasculitis. None of the patients with Hashimoto thyroiditis and toxic nodular goitre, and healthy control subjects had ANCA positivity. PTU therapy is associated with asymptomatic production of ANCA in a time-dependent manner, which mostly disappears after discontinuation of therapy. Hyperthyroidism or autoimmunity per se does not appear to have effect on development of ANCA positivity. |
| | |
Authors:
|
M Ozduman Cin; A Gursoy; Y Morris; O Tiryaki Aydintug; N Kamel; S Gullu |
Related Documents
:
|
6605838 - Lupus pleuritis. clinical features and pleural fluid characteristics with special refer... 2293908 - Down-regulation of autoantibody levels of cyclosporine and bromocriptine treatment in p... 11961428 - Increased lung uptake of technetium-99m hexamethylpropylene amine oxime in systemic lup... 3746838 - Microcephaly, short stature, and developmental delay associated with a chemotactic defe... 15195258 - A multihousehold study reveals a positive correlation between age, severity of ocular t... 14510138 - Idiopathic hypereosinophilic syndrome: a report of four cases in arabs, and a review of... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: International journal of clinical practice Volume: 63 ISSN: 1742-1241 ISO Abbreviation: Int. J. Clin. Pract. Publication Date: 2009 Feb |
Date Detail:
|
Created Date: 2009-02-06 Completed Date: 2010-01-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9712381 Medline TA: Int J Clin Pract Country: England |
Other Details:
|
Languages: eng Pagination: 299-302 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology and Metabolic Diseases, School of Medicine, Ankara University, Ankara, Turkey. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Antineutrophil Cytoplasmic / metabolism* Antithyroid Agents / therapeutic use* Cross-Sectional Studies Female Graves Disease / drug therapy*, immunology Humans Male Middle Aged Propylthiouracil / therapeutic use* Prospective Studies Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Antineutrophil Cytoplasmic; 0/Antithyroid Agents; 51-52-5/Propylthiouracil |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Useful prediction of ureteral calculi visibility on abdominal radiographs based on calculi character...
Next Document: Health benefits of physical activity in older patients: a review.